ACM
IMVT icon

Altium Capital Management’s Immunovant IMVT Stock Holding History

Altium Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-300,000
Closed -$11.5M – 78
2023
Q3 		$11.5M Buy
+300,000
New +$6.78M 6.01% 2

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Altium Capital Management's IMVT Position: Q1 2024 in Review

Altium Capital Management sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 80,000 shares — an estimated $3.37M sold.

Altium Capital Management first reported a position in IMVT in Q4 2020 and held it in 5 quarters. The position peaked at $3.68M in Q1 2021. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Altium Capital Management reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Altium Capital Management sold 80,000 Immunovant shares in Q1 2024, an estimated $3.37M.
  • Altium Capital Management first reported a position in Immunovant in Q4 2020 and held it in 5 quarters.
  • Altium Capital Management's Immunovant position peaked at $3.68M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Altium Capital Management's 13F filing for Q1 2024, filed 15 May 2024.